ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand
Authors:
- Andrea HendenAHAndrea Henden
- Lynette CheeLCLynette Chee
- Julia ClarkJCJulia Clark
- Rachel ConyersRCRachel Conyers
- Julian CooneyJCJulian Cooney
- David GottliebDGDavid Gottlieb
- Tim PrestidgeTPTim Prestidge
- Madeleine PowysMPMadeleine Powys
- Philip SelbyPSPhilip Selby
- Gaurav SutraveGSGaurav Sutrave
- Eric WongEWEric Wong
Open Access
- 10 September 2026
- journal article
- Published by Wiley in Internal Medicine Journal
Abstract
Background: Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. Aims and Methods: To understand the state of practice in Australia, a survey captured insights on detection, monitoring, prophylaxis and treatment from 21 sites, including 11 chimeric antigen receptor T‐cell (CAR‐T) therapy sites. Results: Respondents reported 26 cases of CMV disease after HSCT and four cases after CAR‐T in 2024. All HSCT sites and four CAR‐T sites had CMV protocols. Commonly, CMV nucleic acid viral load (VL) testing was employed weekly. Sites utilised plasma (66%) or whole blood (33%). VL was reported as IU/mL (66%), copies/mL (29%) or not specified (5%). One third of respondents tested CMV DNAemia before HSCT. All recipients were monitored regardless of CMV serostatus. Half the sites employed post‐HSCT CMV prophylaxis using letermovir (nine sites), (val)aciclovir (eight) and (val)ganciclovir (three). VL thresholds for PeT ranged from 100 to 5000 IU/mL. Most sites used (val)ganciclovir for PeT, with foscarnet second line. At 76% of HSCT sites, PeT continued until two consecutive negative results. Frontline therapy for CMV disease is ganciclovir; 86% of ANZ sites used (val)ganciclovir while three paediatric sites used foscarnet. For resistant or refractory CMV, guidelines recommend foscarnet or maribavir, although maribavir was not funded or used during the survey period. CMV‐specific immunotherapy can be considered. Conclusions: Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines.Keywords
This publication has 64 references indexed in Scilit:
- Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplantsInternational Journal of Antimicrobial Agents, 2023
- Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell TransplantationHematology/Oncology and Stem Cell Therapy, 2023
- American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2021
- A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant PatientsClinical Pharmacokinetics, 2021
- Predictors of CMV Reactivation and Survival in Adult Allogeneic HSCT Recipients without CMV ProphylaxisTransplantation and Cellular Therapy, 2020
- Moving Past Ganciclovir and Foscarnet: Advances in CMV TherapyCurrent Hematologic Malignancy Reports, 2020
- Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell ReconstitutionTransplantation and Cellular Therapy, 2018
- Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell TransplantationInfectious Diseases and Therapy, 2017
- Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantationHematology/Oncology and Stem Cell Therapy, 2017
- The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still mattersBlood Reviews, 2017